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Abstract 
Background: Rates of first antiretroviral therapy (cART) modifications are high in most observational studies. The 
age‑related differences in treatment duration and characteristics of first cART modifications remain underinvestigated. 
With increasing proportion of older patients in HIV population it is important to better understand age‑related treat‑
ment effects.
Methods: Patients were included into this analysis, if being cART naïve at the first visit at the clinic. Follow‑up time 
was measured from the first visit date until first cART modification or 28 February 2013. First cART modification was 
defined as any change in the third drug component i.e. protease inhibitor (PI), non‑nucleoside reverse transcriptase 
inhibitor (NNRTI), integrase inhibitor or fusion inhibitor. Cox proportional hazard models were used to identify factors 
related to first cART modification in three age groups: <30, 30–50 and >50.
Results: In total 2027 patients with 14,965 person‑years of follow‑up (PYFU) were included. The oldest group 
included 136 patients with 1901, middle group 1202 with 8416 PYFU and youngest group consisted of 689 patients 
with 4648 PYFU. Median follow‑up time was 5.8 (IQR 3.4–9.4) years, median time on first cART was 4.4 (IQR 2.1–8.5) 
years. 72.4 % of patients started PI‑based and 26.1 % NNRTI‑based regimen. In total 1268 (62.5 %) patients had cART 
modification (non‑adherence 30.8 %, toxicity 29.6 %). Durability of first cART was the best in patients over 50 y.o. (log‑
rank test, p = 0.001). Factors associated with discontinuation in this group were late presentation (HR 0.45, [95 % CI 
0.23–0.90], p = 0.02) and PI use (HR 2.17, [95 % CI 1.18–4.0], p = 0.01).
Conclusions: Rates of first cART modifications or discontinuation were comparable in all groups; however older 
patients were significantly longer on first cART regimen.
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Background
Rates of first combination antiretroviral therapy (cART) 
modifications are high in most observational studies [1–
5]. Recent work from the Antiretroviral Therapy Cohort 
Collaboration (ART-CC) showed that 40.3 % of patients 
modified first cART with no evidence of decrease in 
patients starting treatment more recently [1]. While find-
ings from the Swiss cohort confirm this observation, the 
ATHENA cohort presented almost halved incidence of 
toxicity-related switches between 1996 and 2010 [4, 5]. 
Also, as shown by ICoNA cohort, patients who started 
cART in the ‘recent’ years were less likely to change their 
initial regimen because of intolerance and/or toxicity 
[6]. Such decrease is expected with better availability of 
less toxic and well tolerated treatment options, yet drug-
related toxicities remain the leading cause for treatment 
changes or discontinuations.
With increasing cART utilization, either by earlier ini-
tiation or wider access to treatment, it is of highest pri-
ority to re-evaluate factors associated with antiretroviral 
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drug toxicities occurrence in clinical settings, especially 
in relation to toxicities requiring treatment modifications 
[7–9].
Older age has been linked to increased risk of treat-
ment related toxicities [10–12]. Data from one Italian 
center showed higher rates of toxicity/adverse events 
or personal choice discontinuation among patients over 
50 years of age [3]. In general the age-related differences 
in treatment duration and characteristics of first cART 
modification causes are less evident and remain underin-
vestigated area in pharmacovigilance [13–17].
Most studies focus on comparing patients over and 
less than 50  years of age [3, 17]. As a result a patient 
who is 49  years old would be compared to the one 
being 51, thus just 2  years older. We believe compar-
ing patients across three age groups may better reflect 
possible disparities in treatment durability and modi-
fications. The Collaboration of Observational HIV 
Epidemiological Research Europe study compared age-
related treatment responses across different age strata, 
but information on treatment modifications was not 
presented [18].
Therefore we have investigated first cART durability 
and modification causes comparing three age groups.
Methods
Study design
This is a retrospective, longitudinal analysis of cART 
naïve, HIV-infected adults enrolled in Polish Observa-
tional Cohort of HIV/AIDS Patients (POLCA) study. 
POLCA is an observational database cohort where 
data are collected in real-time from the clinic database. 
The cohort has been established in 1994 with the pur-
pose of prospective, active observation of HIV-positive 
patients routinely followed in HIV Out-Patient Clinic, 
in the Hospital of Infectious Diseases in Warsaw. All 
data are recorded in the electronic database. On the 
day of dataset export the cohort included 3087 HIV-
positive patients 18  years of age or older with 15,814 
person-years of follow-up (PYFU) and 18,269 CD4 cell 
count and 12,090 HIV RNA measurements. In addi-
tion a history of clinical visits, antiretroviral treat-
ment history, demographic characteristics and results 
of all tests performed in the clinic are available for 
each patient. Since 2005 a CoDe procedure has been 
adapted to collect data on death cases in the cohort 
[19]. A central plasma repository has been established 
in 2010.
POLCA is an observational cohort therefore patients 
observed are treated according to standard of care, which 
is following European AIDS Clinical Society guidelines.
All ethical approvals for the study have been obtained 
according to Polish regulations.
Patients and statistical analyses
Patients were included into this analysis, if being cART 
naïve on the first visit at the clinic. Follow-up time was 
measured from the first visit date until first cART modi-
fication or 28 February 2013. First cART modification 
was defined as any change in the third drug component 
i.e. protease inhibitor (PI), non-nucleoside reverse tran-
scriptase inhibitor (NNRTI), integrase inhibitor (ITI) 
or fusion inhibitor (FI). Due to multifactorial origin and 
inability to differentiate between medical or administra-
tive/economic decisions, changes in nucleoside reverse 
transcriptase inhibitors (NRTIs) backbone were not 
considered as modifications. Simplification of treatment 
regimens by changing to combination drugs was not 
considered treatment modification. Discontinuations 
were considered modifications. A reason of treatment 
modification was available in the database as specified by 
patient’s physician via a drop-down selection box avail-
able in the clinic’s database.
Persons presenting in care with a lymphocyte CD4 
count below 350 cells/µL were considered late presenters 
according to European Late Presenter Consensus defini-
tion [20].
Statistical analyses
In statistical analyses Chi squared and Kruskal–Wallis 
tests were used as appropriate, all tests of significance 
were two-sided. Three age groups were defined tak-
ing into accont the age at the first visit in the clinic: <30, 
30–50 and >50 years old. Cox proportional hazard mod-
els were used to identify factors associated with treat-
ment modification. A multivariable model was developed 
including all variables tested in univariate models. The 
potential predictors of treatment modifications tested in 
univariate models were: age, gender, HIV acquisition risk 
group, the lowest (nadir) lymphocyte CD4+ count, anti-
HCV and anti-HBc total antibodies status, baseline hae-
moglobin level, ARV group (PI, NNRTI, ITI or FI) and 
late presentation. Confidence interval (CI) of 95  % was 
accepted. All analyses were performed using SAS version 
9.1 (SAS Institute, Cary, NC, USA).
Results
A total of 2027 patients with 14,965 PYFU were included 
into the study. The group of oldest patients included 136 
patients with 1901 PYFU, middle group 1202 with 8416 
PYFU and youngest patients’ group consisted of 689 
patients with 4648 PYFU.
Median follow-up time was 5.8 (IQR 3.4–9.4) years, 
median time on first cART was 4.4 (IQR 2.1–8.5) years. 
In total 1467 (72.4  %) patients started PI-based cART, 
529 (26.1  %) NNRTI-based and 31 (1.5  %) other cART 
regimen.
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Patients over 50  years of age were more advanced in 
HIV disease with lower first and nadir lymphocyte CD4 
count. They were also more likely to have most recent 
HIV RNA level below 50 copies/ml, to have anti-HBc 
total antibodies positive test result and less likely to have 
anti-HCV antibodies positive tests result. Median age in 
this group was 55.7 (53.0–60.0) years (Table 1).
PI based therapy was most frequent first regimen pre-
scribed in all three groups and the youngest patients were 
shorter on first cART regimen (Table 1).
In total 1268 (62.5  %) patients had treatment modi-
fication. The most common reasons were non-adher-
ence (30.8  %) and treatment related toxicities (29.6  %). 
Approximately 6  % of modifications had no specified 
reason (unknown). Among different causes of treatment 
modification cART failure was more frequent in old-
est patients (p =  0.09), whereas non-adherence in both 
younger groups (p  <  0.001). Toxicities were comparably 
frequent reason for cART change in all age groups. Death 
occurred in 9.6 % of oldest, 3.6 % of middle age and 2.4 % 
of youngest patients, Table 2.
The durability of first cART was better in older patients 
(log rank test, p = 0.001). Fig. 1 presents Kaplan–Meier 
survival curve of time to treatment modification after 
starting first cART regimen stratified by age group.
Factors significantly associated with treatment modifi-
cation in oldest patients’ group were baseline hemoglobin 
level, positive anti-HBs total antibodies status, late pres-
entation and PI use. However in multivariable Cox pro-
portional hazard models analyses only late presentation 
[HR 0.45, (95 % CI 0.23–0.90), p = 0.02] and PI use [HR 
2.17, (95 % CI 1.18–4.0), p = 0.01] remained statistically 
significant (Table 3).
Factors significantly associated with treatment modifi-
cation in middle age group were gender, HIV risk group, 
nadir CD4  +  count, baseline hemoglobin level, positive 
anti-HCV and anti-HBs total antibodies status, late pres-
entation and cART group. In multivariable Cox propor-
tional hazard models analyses male gender (HR 1.50, [95 % 
CI 1.03–2.18], p = 0.034), injecting drug use as HIV infec-
tion mode (HR 0.59, [95 % CI 0.40–0.87], p = 0.007), nadir 
CD4+ count (HR 1.44, [95  % CI 1.32–1.57], p  <  0.001), 
unknown anti-HBc total status (HR 0.67, [95 % CI 0.52–
0.86], p = 0.002), cART group as ITI (HR 24.7, [95 % CI 
9.7–63.4], p < 0.001) and FI (HR 2.73, [95 % CI 1.47–5.04], 
p < 0.001) remained statistically significant (Table 4).
Table 1 Baseline characteristics of all three age groups
* Chi square test
** Abbott RealTime HIV-1 Test
Patients less than  
30 y.o. N = 689, N (%)
Patients  
30–50 y.o., N (%)
Patients over  
50 y.o. N = 136, N (%)
P value*
Female 217 (26.3) 169 (14.1) 15 (11.0) <0.0001
MSM 268 (38.9) 505 (24.9) 48 (35.3) <0.0001
Positive anti‑HCV antibodies 231 (33.5) 361 (30.0) 20 (14.7) <0.001
Positive anti‑HBc total antibodies 144 (20.9) 376 (31.3) 60 (44.1) <0.0001
Positive VDRL 98 (14.2) 216 (18.0) 21 (15.4) 0.17
Late presenters (CD4 <350) 293 (42.5) 661 (55.0) 87 (64.0) <0.0001
First cART 0.79
 PI 491 (71.3) 880 (73.2) 96 (70.6)
 NNRTI 188 (27.3) 303 (25.2) 38 (27.9)
 Any cART modification 414 (60.1) 771 (64.1) 83 (61.0) 0.20
 Last HIV RNA <50** *opies/ml* 543 (64.7) 952 (79.2) 126 (86.9) <0.0001
Median (IQR)
Age in years 26.6 (23.8–28.4) 35.9 (32.4–40.3) 55.7 (53–60) –
Haemoglobin level 14.1 (13.0–15.1) 14.0 (12.6–15.1) 13.3 (11.5–14.2) <0.0001
First CD4 (cells/µl) 416 (268–570) 317 (163–184) 240 (80–480) <0.0001
Nadir CD4 (cells/µl) 244 (143–337) 173 (69–274) 166 (61–301) <0.0001
Last CD4 (cells/µl) 504 (367–673) 476 (315–638) 488 (356–631) 0.012
First HIV RNA (log10 copies/ml)** 4.33 (3.56–4.87) 4.38 (3.40–4.99) 4.43 (3.02–5.01) 0.54
Follow‑up time in years 5.1 (3.2–8.3) 6.1 (3.4–10.1) 5.2 (3.6–9.2) <0.0001
Time on cART in years 3.4 (1.7–7.3) 4.8 (2.4–9.0) 4.8 (2.0–8.5) <0.0001
Time on first cART in years 1.4 (0.5–2.8) 2.0 (0.8–3.8) 2.0 (0.7–4.1) <0.0001
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In the group of youngest patients gender, HIV risk 
group, nadir CD4+ count, baseline hemoglobin level, 
positive anti-HBs total and anti HCV antibodies status 
were significantly associated with treatment modification 
in univariate analyses. After adjustment for confound-
ing variables only nadir CD4+ count remained signifi-
cant factors decreasing the risk of modification (HR 0.89, 
[95 % CI 0.81–0.98], p = 0.017), (Table 5).
Discussion
In this study we present that patients over 50  years of 
age had much better treatment durability as compared 
to other age groups. Factors significantly increasing 
the risk of cART modification in this group of patients 
were PI use and late presentation. Although rates of first 
cART modifications were comparable in both groups, 
treatment discontinuation due to its toxicity or failure 
was more frequent among oldest patients, whereas due 
to non-adherence in younger patients. This is to our 
knowledge the first study to present such age-related 
differences in the frequency of the discontinuation 
causes.
Co-infections and co-morbidities are more frequent in 
patients over 50, thus toxicities more likely to occur and 
more likely to be the cause of treatment modifications 
[21, 22]. However, in our work rates of modifications 
related to non-HIV diseases were only slightly increasing 
across age groups, being in general a rare cause of switch-
ing. The additional challenge for starting cART in older 
persons is polypharmacy [23], however in our analyses 
we were not able to control for this factor.
Interestingly PI based cART regimens were preferable 
in all groups and in older patients were associated with 
increased risk of treatment modification. Higher PI utili-
zation may reflect the need to initiate treatment immedi-
ately due to low CD4+ lymphocyte count and when the 
genotyping test result is not yet available. Although the 
primary mutations are infrequent in Poland it is generally 
preferred to receive genotyping test result before starting 
treatment [24]. This could lead to the increased utilisa-
tion of PIs in patients initiating cART in our study.
We found that older patients had better viral suppres-
sion, defined by the proportion of patients with latest 
HIV RNA level below 50 copies/ml. Studies investigating 
effects of age on treatment response are inconsistent and 
does not provide insight into failure related modifications 
across age groups [17, 18, 25]. According to COHERE the 
probability of virological response was higher for persons 
aged 50–59 as compared to 30–39 years old [18].
In our study late presentation was 20 % higher in older 
patients and only in this group of patients significantly 
associated with lower risk of treatment modification. 
Studies of large HIV-positive populations present lower 
lymphocyte CD4+ count and shorter time to AIDS for 
older patients, which is well in line with higher rate of 
late presenters among older patients in most observa-
tional cohorts [14]. In a large nationwide study in the 
Table 2 Comparison of reasons for treatment modification between older and younger patients
* p value < 0.001
Reason for treatment modification Patients less than 30 Patients from 30 to 50 y.o. Patients over 50 P value*
Total 441 (100) 771 (100) 83 (100) –
cART toxicity 136 (32.8) 232 (30.2) 30 (36.1) 0.41
cART failure 20 (4.8) 50 (6.5) 9 (10.8) 0.09
Non‑HIV related disease 8 (1.9) 17 (2.2) 2 (2.4) 0.89
Non‑adherence 116 (28.0) 262 (34.0) 13 (15.7) <0.001
Pregnancy 12 (2.9) 1 (0.1) 0 (0.0) <0.0001
Migration 21 (5.1) 55 (7.1) 3 (3.6) 0.15
Death 10 (2.4) 28 (3.6) 8 (9.6) 0.006
Other 65 (15.7) 80 (10.4) 13 (15.7) 0.07
Unknown 26 (6.3) 46 (6.0) 5 (6.0) 1.00
Fig. 1 Kaplan‑Meier survival curve for the time to treatment modifi‑
cation after starting first cART regimen
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United Kingdom late presenters were more likely to 
be over 50  years of age and contributed to 67  % of all 
patients over 50 [26]. This findings are showing an urgent 
need for improved testing strategies, as increasing utili-
zation of HIV testing among older persons may result in 
earlier HIV diagnosis [27–29].
The presented lower rate of non-adherence related 
treatment modification in older patients is well in line 
with data published by other cohorts [30].
There are some limitations, which need to be high-
lighted. We focused exclusively on the third drug in 
regimen. We estimate that differences presented in our 
work would be even more profound, should the NRTI 
group switching be included. Due to small numbers we 
were not able to investigate further the effects of spe-
cific antiretroviral drugs and the drug-related risk of 
ART discontinuation [31]. We have not investigated 
the impact of cART modifications on mortality due to 
small number of deaths in the investigated group of 
patients. Whether and to what extent treatment mod-
ifications influence the general treatment outcome 
measured as mortality remains especially important 
in older patients, thus should remain in future studies 
focus [16].
It needs to be mentioned that our study’s background 
may vary from other countries and/or regions in terms 
of demographics, preferred first line treatment regimens 
and timing of treatment initiation.
Table 3 Univariate and  multivariate hazard ratios of  the risk of  treatment modification in  the group of  patients 
over 50 years old
a Adjusted for all above
Unvariate Multivariatea
P value Hazard  
ratio
95 % hazard ratio  
confidence limits
P value Hazard  
ratio
95 % hazard ratio 
confidence limits
Gender
 Male 0.14 0.61 0.31 1.81 0.37 0.71 0.33 1.51
 Female – 1.00 – – – 1.00 – –
HIV risk group
 MSM 0.08 0.62 0.36 1.06 0.09 0.60 0.33 1.09
 Heterosexual – 1.00 – – – 1.00 – –
 IDU 0.33 1.41 0.70 2.84 0.58 1.29 0.52 3.21
 Other 0.44 0.70 0.28 1.74 0.50 0.72 0.28 1.85
 Unknown 0.37 0.72 0.35 1.48 0.52 0.78 0.37 1.66
Nadir CD4 value
 Per 100 increase 0.62 1.05 0.87 1.25 0.18 0.84 0.66 1.08
Age in years
 Per 1 year increase 0.87 1.00 0.97 1.04 0.73 1.01 0.97 1.05
Anti‑HCV Ab
 Positive 0.22 1.43 0.80 2.54 0.33 0.65 0.28 1.53
 Negative – 1.00 – – – 1.00 – –
 Unknown 0.55 0.77 0.33 1.81 0.29 0.60 0.23 1.56
Anti‑HBc Ab
 Positive 0.50 1.2 0.7 2.06 0.30 1.36 0.76 2.45
 Negative – 1.00 – – – 1.00 – –
 Unknown 0.29 1.37 0.76 2.46 0.36 1.37 0.70 2.71
Baseline hemoglobin
 Per 1 g/dL increase 0.05 1.02 1.0 1.04 0.14 1.01 0.995 1.04
ARV group
 PI 0.03 1.79 1.06 3.02 0.01 2.17 1.18 3.98
 NNRTI – 1.00 – – – 1.00 – –
 ITI 0.99 0 0 0 0.99 0 0 –
 FI 0.99 0 0 0 0.99 0 0 –
Late presentation
 Yes 0.03 0.61 0.39 0.96 0.02 0.45 0.23 0.90
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Although persons over 50  years old are contribut-
ing to approximately half of HIV-positive population 
treatment modifications in this group of patients are 
rarely investigated [32]. Studies should focus on this 
important area in order to better adjust HIV care to 
patient needs and age related health problems. Such 
approach could significantly contribute to further 
decrease in morbidity and mortality of HIV-positive 
population.
Conclusions
Although rates of first cART modifications in our study 
were comparable between age groups, we have shown a 
substantial differences in reasons for treatment modifica-
tion. Older patients were also significantly longer on first 
cART regimen. In multivariate Cox proportional hazard 
models factors significantly increasing the risk of cART 
modification in older patients included late presentation 
and PI use. Our findings present age-related differences 
Table 4 Univariate and multivariate hazard ratios of the risk of treatment modification in the group of patients 30 years 
old to 50 years old
Parameter Unvariate Multivariate
P value Hazard  
ratio
95 % hazard ratio  
confidence limits
P value Hazard  
ratio
95 % hazard ratio 
confidence limits
Gender
 Male <0.001 1.95 1.40 2.73 0.034 1.50 1.03 2.18
 Female – 1.00 – – – 1.00 – –
HIV risk group
 MSM <0.001 1.71 1.31 2.23 0.09 1.29 0.96 1.72
 Heterosexual – 1.00 – – – 1.00 – –
 IDU 0.002 0.57 0.41 0.81 0.007 0.59 0.40 0.87
 Other 0.11 0.55 0.27 1.15 0.12 0.56 0.27 1.17
 UNKN 0.74 1.07 0.71 1.61 0.94 1.02 0.67 1.55
Nadir CD4 value
 Per 100 increase <0.001 1.46 1.37 1.56 <0.001 1.44 1.32 1.57
Age in years
 Per 1 year increase 0.50 0.99 0.98 1.01 0.29 0.99 0.97 1.01
Anti‑HCV Ab
 Positive <0.001 0.40 0.31 0.53 0.24 0.81 0.56 1.16
 Negative – 1.00 – – – 1.00 – –
 Unknown 0.45 0.88 0.63 1.23 0.06 1.44 0.98 2.11
Anti‑HBc Ab
 Positive <0.001 0.60 0.48 0.76 0.07 0.79 0.62 1.02
 Negative – 1.00 – – – 1.00 – –
 Unknown <0.001 0.59 0.47 0.74 0.002 0.67 0.52 0.86
Baseline hemoglobin
 Per 1 g/dL increase 0.09 1.01 1.00 1.03 0.57 0.99 0.95 1.03
ARV group
 PI 0.35 1.11 0.89 1.38 0.18 1.16 0.93 1.46
 NNRTI – 1.00 – – – 1.00 – –
 ITI <0.001 22.9 9.14 57.5 <0.001 24.7 9.66 63.4
 FI <0.001 3.85 2.11 7.02 0.001 2.73 1.47 5.04
Late presenter
 Yes <0.001 0.65 0.54 0.78 0.79 1.05 0.83 1.33
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in terms of treatment tolerability warranting the need for 
further studies in this area, as well as opening a discussion 
about age-adjusted approach in HIV treatment strategies.
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